R-CHOP plus thalidomide for previously untreated patients with mantle cell lymphoma (AGMT NHL-11 trial)

Drach, J, Hopfinger, G, Fridrik, M, Greil, R, Thaler, J, Willenbacher, W, Lang, A, Jager, U, Raderer, M ONKOLOGIE. 2011, 34: 75-75.

DOSE-ESCALATION WITH BEACOPP ESCALATED IS SUPERIOR TO ABVD IN THE COMBINED-MODALITY TREATMENT OF EARLY UNFAVORABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL

Borchmann, P, Diehl, V, Plutschow, A, Von Tresckow, B, Markova, J, Hitz, F, Kra, Z, Greil, R, Topp, MS, Villalobos, M, Zijlstra, JM, Sokler, M, Fuchs, M, Engert, A ANN ONCOL. 2011, 22: 180-180.

Lower incidence of BCR-ABL mutations and improved molecular response kinetics in newly diagnosed CML patients treated with nilotinib compared with imatinib

Muller, MC, le Coutre, P, Gattermann, N, Scheid, C, Al-Ali, HK, Ottmann, OG, Duyster, J, Blumenstengel, K, Brummendorf, TH, Greil, R, Chalandon, Y, Valent, P, Stegelmann, F, Kneba, M, Schafhausen, P, Saussele, S, Frank, O, Larson, RA, Saglio, G, Hochhaus, A, Lange, T ONKOLOGIE. 2011, 34: 266-266.

62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer

Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Poestlberger, S, Steger, G, Jakesz, R, Singer, C, Eidtmann, H, Greil, R BONE. 2011, 48(1): S17-S17.

The oncogenic miR-17-92 cluster and miR-155 define ALK status in anaplastic large cell lymphoma

Griessl, R, Hamacher, F, Sifft, E, Scheideler, M, Kenner, L, Greil, R, Merkel, O ONKOLOGIE. 2011, 34: 135-135.

Parp Inhibitoren

Ressler Sigrun, Mlineritsch Brigitte, Greil Richard Universum Innere Medizin. 2011.

Bisphosphonate in der Therapie des Mammakarzinoms

Ressler Sigrun, Mlineritsch Brigitte, Greil Richard MEDIUM. 2011. 3: 26-30.

Bedeutung des RANK / RANK-Ligand Systems beim Mammakarzinom: Biologische Grundlagen.

Ressler Sigrun, Mlineritsch Brigitte, Greil Richard Universum Innere Medizin. 2011.

Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

Gökbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernández-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D Haematologica. 2011 Feb,96(2):238-44. doi: 10.3324/haematol.2010.028092. Epub 2010 Oct 15.

Infusion reactions to the chimeric EGFR inhibitor cetuximab–change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.

Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J. Ann Oncol. 2011 Feb,22(2):486-7. doi: 10.1093/annonc/mdq744. Epub 2011 Jan 13.